336 related articles for article (PubMed ID: 18537788)
1. Superiority, equivalence, and non-inferiority trials.
Lesaffre E
Bull NYU Hosp Jt Dis; 2008; 66(2):150-4. PubMed ID: 18537788
[TBL] [Abstract][Full Text] [Related]
2. Use and misuse of the p-value.
Lesaffre E
Bull NYU Hosp Jt Dis; 2008; 66(2):146-9. PubMed ID: 18537787
[TBL] [Abstract][Full Text] [Related]
3. Responder analysis and correlation of outcome measures: pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis.
Bingham CO; Bird SR; Smugar SS; Xu X; Tershakovec AM
Osteoarthritis Cartilage; 2008 Nov; 16(11):1289-93. PubMed ID: 18514551
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
Bingham CO; Sebba AI; Rubin BR; Ruoff GE; Kremer J; Bird S; Smugar SS; Fitzgerald BJ; O'Brien K; Tershakovec AM
Rheumatology (Oxford); 2007 Mar; 46(3):496-507. PubMed ID: 16936327
[TBL] [Abstract][Full Text] [Related]
5. Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo.
Bingham CO; Smugar SS; Wang H; Tershakovec AM
Rheumatology (Oxford); 2009 Sep; 48(9):1122-7. PubMed ID: 19589894
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
Schnitzer TJ; Weaver AL; Polis AB; Petruschke RA; Geba GP;
J Rheumatol; 2005 Jun; 32(6):1093-105. PubMed ID: 15940774
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
Sheldon E; Beaulieu A; Paster Z; Dutta D; Yu S; Sloan VS
Clin Ther; 2005 Jan; 27(1):64-77. PubMed ID: 15763607
[TBL] [Abstract][Full Text] [Related]
8. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis.
Pincus T; Koch G; Lei H; Mangal B; Sokka T; Moskowitz R; Wolfe F; Gibofsky A; Simon L; Zlotnick S; Fort JG
Ann Rheum Dis; 2004 Aug; 63(8):931-9. PubMed ID: 15082468
[TBL] [Abstract][Full Text] [Related]
9. Antiinflammatory and analgesic efficacy of COX-2 specific inhibition: from investigational trials to clinical experience.
Bensen WG
J Rheumatol Suppl; 2000 Oct; 60():17-24. PubMed ID: 11032098
[TBL] [Abstract][Full Text] [Related]
10. [The efficacy of selective Cox-2-inhibitors in comparison with conventional NSAIDs].
Krüger K
MMW Fortschr Med; 2005 Aug; 147(31-32):28-30. PubMed ID: 16128193
[TBL] [Abstract][Full Text] [Related]
11. COX-2 inhibitor.
Gøtzsche PC; Bjarnason NH
Rheumatology (Oxford); 2007 Oct; 46(10):1623-4; author reply 1624-5. PubMed ID: 17726033
[No Abstract] [Full Text] [Related]
12. Celecoxib 200 mg q.d. is efficacious in the management of osteoarthritis of the knee or hip regardless of the time of dosing.
Stengaard-Pedersen K; Ekesbo R; Karvonen AL; Lyster M
Rheumatology (Oxford); 2004 May; 43(5):592-5. PubMed ID: 14762227
[TBL] [Abstract][Full Text] [Related]
13. Celecoxib improves the efficiency of the locomotor mechanism in patients with knee osteoarthritis. A randomised, placebo, double-blind and cross-over trial.
Detrembleur C; De Nayer J; van den Hecke A
Osteoarthritis Cartilage; 2005 Mar; 13(3):206-10. PubMed ID: 15727886
[TBL] [Abstract][Full Text] [Related]
14. Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial.
DeLemos BP; Xiang J; Benson C; Gana TJ; Pascual ML; Rosanna R; Fleming B
Am J Ther; 2011 May; 18(3):216-26. PubMed ID: 20215961
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults.
Kivitz A; Fairfax M; Sheldon EA; Xiang Q; Jones BA; Gammaitoni AR; Gould EM
Clin Ther; 2008 Dec; 30(12):2366-77. PubMed ID: 19167595
[TBL] [Abstract][Full Text] [Related]
16. [Homeopathy suppresses COX- and LOX activity. Soft therapy for arthrosis ills].
MMW Fortschr Med; 2004 Jan; 146(5):47. PubMed ID: 15035421
[No Abstract] [Full Text] [Related]
17. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial.
Gibofsky A; Williams GW; McKenna F; Fort JG
Arthritis Rheum; 2003 Nov; 48(11):3102-11. PubMed ID: 14613272
[TBL] [Abstract][Full Text] [Related]
18. Treatment of osteoarthritis with continuous versus intermittent celecoxib.
Strand V; Simon LS; Dougados M; Sands GH; Bhadra P; Breazna A; Immitt J
J Rheumatol; 2011 Dec; 38(12):2625-34. PubMed ID: 22045833
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain.
Schnitzer TJ; Ekman EF; Spierings EL; Greenberg HS; Smith MD; Brown MT; West CR; Verburg KM
Ann Rheum Dis; 2015 Jun; 74(6):1202-11. PubMed ID: 24625625
[TBL] [Abstract][Full Text] [Related]
20. Pragmatic decisions over nonsteroidal antiinflammatory drug treatment in osteoarthritis--continuous versus intermittent.
Moore RA
J Rheumatol; 2011 Dec; 38(12):2501-3. PubMed ID: 22134793
[No Abstract] [Full Text] [Related]
[Next] [New Search]
